Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Women can stand the cold BETTER than men, surprising study finds
It's long been thought that women feel the cold more than men.But a new study suggests otherwise – a2024-05-01Man arrested after authorities say he threw pipe bomb at Satanic Temple
BOSTON (AP) — An Oklahoma man was arrested Wednesday after authorities accused him of throwing a pip2024-05-01Report: China is exporting digital control methods — Radio Free Asia
China’s government has turned the country’s tech companies like Huawei and ZTE into its “proxies” an2024-05-01- BALTIMORE (AP) — Cedric Mullins hit a two-run homer in the bottom of the ninth inning to give the Ba2024-05-01
- JERUSALEM (AP) — A Portuguese-flagged container ship came under attack by a drone in the far reaches2024-05-01
The Padres have put pitcher Yu Darvish on the 15
MILWAUKEE (AP) — The San Diego Padres have put right-hander Yu Darvish on the 15-day injured list wi2024-05-01
atest comment